Method for detecting methylation and mutation states of DNA sample

PCR amplification using methylation-sensitive restriction enzymes and specific primers in DNA samples, combined with mutation and methylation capture probes, solves the difficulty of detecting methylation and mutation status in the prior art. The problem of this has achieved efficient and low-cost co-detection effect.

WO2025000669A1PCT designated stage expired Publication Date: 2025-01-02NANODIGMBIO (NANJING) BIOTECHNOLOGY CO LTD

Patent Information

Application Number
PCT/CN2023/114356
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-06-29
Filing Date
2023-09-27
Publication Date
2025-01-02

AI Technical Summary

Technical Problem

Existing detection technologies are difficult to detect methylation and mutation status in DNA samples at the same time. Traditional methods require two independent libraries and hybrid capture systems, which are cost-effective and inefficient, and cannot achieve mutations and ana in the same hybrid capture system. Co-detection of the system.

Method used

By adding linker molecules to DNA samples, using methylation-sensitive restriction enzymes for enzyme cleavage, separating and uncleared samples, combining specific primers for PCR amplification, using mutation capture probe Needle and methylation capture probes are targeted to determine the methylation and mutation status by sequencing depth ratios.

Benefits of technology

It realizes the simultaneous detection of methylation and mutation status of DNA samples in the same hybridization capture system, shortens the detection time, simplifies the experimental process, reduces the cost of reagents, and improves sample utilization.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2023114356_02012025_PF_FP_ABST
    Figure CN2023114356_02012025_PF_FP_ABST
Patent Text Reader

Abstract

The present invention provides a method for detecting methylation and mutation states of a DNA sample, and particularly provides a method for simultaneously detecting a methylation state and a mutation state of a DNA molecule in a sample. The method comprises: using a methylation-sensitive restriction endonuclease to treat a sample; using a probe group comprising a mutation capture probe and a methylation capture probe to perform hybridization capture on amplification products of the sample treated with the restriction endonuclease and a sample having not been subjected to enzyme digestion treatment; and performing sequencing on captured products.
Need to check novelty before this filing date? Find Prior Art

Description

A method for detecting methylation and mutation status of DNA samples

[0001] This application claims priority to Chinese patent application No. 2023107826914 filed with the Patent Office of China on June 29, 2023, the entire text of which is hereby incorporated by reference. Technical Field

[0002] The present invention relates to a method for simultaneously detecting methylation and mutation status, and completes methylation and / or mutation detection of a target region by capturing. Background Art

[0003] According to statistics, in 2022, there were approximately 4.82 million new cancer cases and 3.21 million cancer deaths in China. Cancer has become a globally recognized public health issue. Early cancer screening and diagnosis are important ways to reduce cancer mortality. According to a report on early detection of multiple cancer types released by Grand View Research, Inc., the global market size for early detection of multiple cancer types is expected to reach US$2.77 billion by 2030, and will grow at a compound annual growth rate of 15.80% from 2022 to 2030. The rise of multi-cancer early detection technology is of epoch-making significance for early cancer screening and diagnosis. Compared with single-cancer detection, multi-cancer detection can detect multiple cancers at a time and has become the future development trend of the industry. With the development of the early cancer screening industry and the expansion of the market size, more and more companies are focusing on early cancer screening, making the leap from single cancer type to multiple cancer types.

[0004] Early cancer screening methods in clinical practice include imaging, endoscopy, and tumor markers. These technologies suffer from drawbacks such as invasiveness, discomfort, and low sensitivity. Traditional methods have various limitations, and there is an urgent need for early screening technologies with high sensitivity and specificity and ease of use. Liquid biopsy, as a new, non-invasive testing technology, holds enormous potential for early cancer screening. Tumor markers in liquid biopsies primarily encompass genomic, epigenetic, transcriptomic, microbiome, proteomic, and metabolomic dimensions. Tumor marker characteristics at the ctDNA level include point mutations, fragmentation, copy number changes, and methylation. Mutations are a key area of ​​expertise for genetic testing companies. However, early-stage cancer mutation signals are weak, making detection challenging. Furthermore, mutation signals are easily confounded by clonal hematopoietic signals, lack tumor specificity, and are difficult to trace to the site of tumorigenesis. Methylation markers, with their stable presence in plasma, numerous mutation sites, and tissue tracing capabilities, have made them a preferred biomarker for early cancer screening. Cancer development and progression involve changes at multiple levels, and single-level assessments have limitations. Therefore, "multi-omics" has become a popular term in the field of early cancer screening and tumor detection. The combination of mutation and methylation detection technologies can complement each other and facilitate the implementation of early screening for multiple cancer types.

[0005] There are many types of methylation sequencing methods. First- and second-generation sequencing technologies can only distinguish between the four different bases of ATCG and cannot distinguish between methylated and unmethylated C bases. The traditional treatment solution is to use bisulfite conversion to convert the unmethylated C base into a U base. After PCR amplification, the U base is converted into T and compared with the unconverted sequence to determine whether methylation modification has occurred at the site. However, the converted sequence is different from the original sequence, so based on the liquid-phase hybridization capture solution of the existing system, the experimental purpose of co-detection of mutations and methylation cannot be achieved in the same hybridization capture system. Therefore, there is no way to perform methylation detection and mutation detection at the same time.

[0006] Summary of the Invention

[0007] This article provides a method for simultaneously detecting the methylation status and mutation status of DNA molecules in a sample, including:

[0008] 1) adding adapter molecules to both ends of the DNA molecules in the sample to obtain an adapter ligation product sample; dividing the adapter ligation product sample into two parts: a first adapter ligation product sample and a second adapter ligation product sample;

[0009] 2) treating the first adapter-ligated product sample with one or more methylation-sensitive restriction endonucleases to enable an enzyme digestion reaction when the DNA molecule is not methylated at the recognition site of the methylation-sensitive restriction endonuclease, thereby obtaining an enzyme digestion sample; and the second adapter-ligated product sample is not treated with the restriction endonuclease;

[0010] 3) using primers specific to the adapter molecule and having an index sequence to amplify the enzyme-digested sample and the second adapter-ligated product sample, respectively, to obtain enzyme-digested sample amplification products and second adapter-ligated product sample amplification products, respectively; mixing the enzyme-digested sample amplification products and the second adapter-ligated product sample amplification products to obtain an amplification product mixture;

[0011] 4) contacting the amplicon mixture with a probe set comprising one or more mutation capture probes and one or more methylation capture probes to obtain a capture, wherein the methylation capture probe targets a target sequence comprising the recognition site in the DNA molecule, and the mutation capture probe targets a target sequence comprising the mutation site in the DNA molecule; and

[0012] 5) Sequencing the captured product, determining the methylation state of the DNA molecule including the recognition site by the sequencing depth ratio of the recognition site from the enzyme-cleaved sample amplicon and the second adapter-ligated product sample amplicon, and determining the mutation state by the sequencing result of the mutation site.

[0013] In some embodiments, the mutation capture probe and / or the methylation capture probe includes a target-specific sequence, a first probe binding sequence located at the 5' end of the target-specific sequence, and a second probe binding sequence located at the 3' end of the target-specific sequence, and the first probe binding sequence is at least partially complementary to the second probe binding sequence, so that when two or more of the mutation capture probes and / or the methylation capture probes bind to their target sequences in an adjacent manner, the adjacent mutation capture probes and / or the methylation capture probes can form complementary binding through the first probe binding sequence and the second probe sequence.

[0014] In some embodiments, the probe panel further comprises one or more normalization probes.

[0015] In some embodiments, the first probe binding sequence and the second probe binding sequence are 8-30 nt in length.

[0016] In some embodiments, the target-specific sequence is 20-80 nt in length.

[0017] In some embodiments, the method further comprises fragmenting the DNA molecule before step 1).

[0018] In some embodiments, the methylation-sensitive restriction endonuclease is selected from Hpa I, Hpa II, Hha I, Aci I, and any combination thereof.

[0019] In some embodiments, the sample comprises ctDNA.

[0020] In some embodiments, the methylation status includes whether methylated and / or the methylation level.

[0021] In some embodiments, the mutation status includes the presence or absence of a mutation and / or the type of mutation.

[0022] In some embodiments, the mutation type is selected from the group consisting of insertion, deletion, and substitution of bases, and chromosome copy number variation, microsatellite instability, and fusion genes. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 shows the capture library construction process.

[0024] Figure 2 shows the experimental process of capture and mutation co-detection and the corresponding probe design scheme. (A) The experiment is started according to the experimental process described in Figure 1; after the adapter product is connected, it is digested with a methylation-sensitive restriction endonuclease. The library constructed by the digestion product is used for methylation status detection, and the non-digested library is used for mutation detection; (B) The experiment is started according to the experimental process described in Figure 1; after the adapter product is connected, it is digested with a methylation-sensitive restriction endonuclease. The library constructed by the digestion product is used for methylation status and mutation detection status analysis. (C) Probe design ideas, for methylation detection, the probe needs to cover the methylation-sensitive restriction endonuclease cleavage site. For mutation site detection, the probe covers the gene site to be detected. If the experimental process B is used, the design of the mutation detection probe must take into account methylation detection, and the designed probe cannot cover the methylation-sensitive restriction endonuclease cleavage site.

[0025] Figure 3 shows a comparison of the experimental processes for mutation and methylation detection between the traditional detection scheme and the scheme adopted by the present invention. (A) The process of mutation and methylation detection by the traditional detection scheme, which requires the construction of two sets of libraries and the implementation of two sets of hybridization capture experiments. Among them, the methylation library uses a methylation-modified connector, which has a high connector cost. The connector connection product is processed using a BS or EM conversion module to convert the unmethylated modified C base into a U base. (B) The mutation and methylation co-detection scheme of the present invention uses conventional DNA connectors and MSRE for enzyme digestion to distinguish between methylated and unmethylated modified C bases. A DNA library is systematically constructed, or the connector connection product is divided into two parts, one part is amplified after enzyme digestion, and the other part is directly amplified. The two amplified products can be hybridized in the same hybridization capture system.

[0026] Figure 4 shows the experimental workflow and off-machine quality control results. (A) Experimental workflow; (B) Performance results: [On-Target] Fraction of Target Reads in Mapped Reads, the ratio of on-target reads to read length; Mappability, the proportion of data mapped to the genome; (C) 0.5× Mean Coverage, 0.5× average coverage percentage; 0.2× Mean Coverage, 0.2× average coverage percentage.

[0027] Figure 5 shows the sequencing depth and corresponding methylation levels of methylation-sensitive endonucleases within the target regions of different libraries. Methylation levels are calculated as: enzyme digestion depth / control depth; (A) Average CpG methylation levels in the two enzyme digestion experimental groups; (B) The corresponding methylation level for each CpG site.

[0028] Figure 6 shows the results of the consistency analysis of mutation detection analysis in the captured data and the theoretical mutation frequencies. DETAILED DESCRIPTION

[0029] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art.

[0030] The term "or" refers to a single element of the listed alternative elements, unless the context clearly indicates otherwise. The term "and / or" refers to any one, any two, any three, any more or all of the listed alternative elements.

[0031] The terms "include", "comprising", "having" and similar expressions used herein do not exclude unrecited elements. These terms also include the case where the composition consists of only the listed elements.

[0032] "DNA molecule" herein refers to deoxyribonucleic acid, which is a polymer of deoxyribonucleotides. It can be in double-stranded form or single-stranded form, or for a population of DNA molecules, it can include double-stranded DNA molecules and single-stranded DNA molecules. DNA molecules can be of any length, for example, genomic DNA, DNA fragments, or extracellular free DNA. Free DNA refers to DNA that is free outside the cell or outside the cell nucleus and can be extracted from various body fluids, in vitro cell culture fluid, natural environment and other biological materials, including but not limited to: peripheral blood, plasma, serum, urine, feces, saliva, cerebrospinal fluid, lymph fluid, etc. Free DNA can be obtained through extraction and purification. "DNA fragment" herein refers to a shorter DNA molecule, for example, with a length between 50bp and 700bp, for example, 100bp to 500bp, and especially 100bp to 350bp. The DNA fragments contained in a biological sample are usually heterogeneous, that is, the lengths are different. Accordingly, the above-mentioned length can refer to the mean length of these DNA fragments. These DNA fragments may have different sequences, for example, from different regions of the genome of the same organism, or even from different organisms. The DNA fragments may have single-stranded nicks and may have blunt or non-blunt ends (with 3' or 5' overhangs).

[0033] "DNA methylation" in this context refers to the methylation of bases within a DNA molecule or DNA fragment, specifically the modification of cytosine to 5-methylcytosine (5mC). In vertebrates, DNA methylation typically occurs at CpG sites (i.e., sites in a DNA sequence where cytosine is immediately followed by a guanine), where DNA methyltransferases catalyze the conversion of cytosine to 5-methylcytosine. While most CpG sites in the human genome are methylated, certain specific regions, such as CpG islands rich in cytosine (C) and guanine (G), are typically unmethylated. CpG methylation can affect the transcriptional activity of related genes. For example, methylation can inhibit tumor suppressor genes, while demethylation can stimulate the expression of certain oncogenes, potentially leading to the development of cancer. Furthermore, although the incidence is lower than that of 5mC, a small number of cytosine bases are modified to 5-hydroxymethylcytosine (5hmC), 5-formylation (5fC), and 5-carboxylation (5caC). When methylation is mentioned herein, it may also refer to modifications such as 5hmC, 5fC, and 5caC, unless the context indicates otherwise.

[0034] "Cytosine base methylation status" or "DNA methylation information" in this article refers to information about the methylation status in a DNA molecule or DNA fragment, including but not limited to methylation sites, methylation levels, methylation patterns (such as 5mC or 5hmC), etc. "Methylation level", also known as "methylation degree", refers to the proportion (or frequency) of a specific methylation site in a sample that is modified by methylation. There are many ways to detect whether a site is methylated. Common methods include chemical or enzymatic conversion, during which one of the methylated cytosine and unmethylated cytosine is converted into uracil (U) or a base that is substantially equivalent to uracil in base pairing (such as dihydrouracil, DHU). In the subsequent amplification process, the corresponding uracil pairs with adenine (A) as thymine (T), and the final result is that the cytosine or methylated cytosine at the methylation site is reflected as thymine in the test results (such as sequencing results). By comparing with the reference sequence, it is possible to determine whether the cytosine in the DNA molecule or DNA fragment is methylated. The reference sequence can be a sequence from the same sample but without the above-mentioned conversion, or a corresponding sequence in a healthy population. 5mC and 5hmC can also be distinguished by some methods. Currently, DNA methylation information has been widely used in cancer (e.g., lung cancer, breast cancer, liver cancer, colorectal cancer, etc.) screening and diagnosis, especially early screening and diagnosis. In addition, the identification of methylation status can also be used for non-diagnostic (or therapeutic) purposes, such as for scientific research, such as analyzing factors that affect methylation, the effect of methylation on gene function, or for the detection of methylation standards, etc.

[0035] "Methylation-sensitive restriction endonucleases" refer to restriction endonucleases that are sensitive to the presence of methylated bases in their recognition sites. Such enzymes generally cannot cleave DNA molecules at their recognition sites if they contain a methylated base. Herein, methylation-sensitive restriction endonucleases specifically refer to restriction endonucleases that cannot cleave DNA molecules at their recognition sites if they contain at least one 5mC. Methylation-sensitive restriction endonucleases known in the art include, but are not limited to, Hpa I, Hpa II, Hha I, and Aci I.

[0036] "Capture probe" refers to a single-stranded DNA fragment used to hybridize with a target DNA molecule in this article. In this article, capture probes include methylation capture probes and mutation capture probes. The methylation capture probe used preferably targets a target sequence containing a restriction endonuclease recognition site in a DNA molecule. If the methylation state of the recognition site of a DNA molecule treated with a specific restriction endonuclease enables the restriction endonuclease to cut the DNA molecule, the capture probe will only partially or insufficiently bind to the target DNA molecule, thereby failing to effectively separate the target DNA molecule cut by the restriction endonuclease from the sample. In this case, the target DNA molecules that can be separated from the sample treated with the restriction endonuclease using the methylation capture probe are mainly DNA molecules that have not been cut by the enzyme. Therefore, the overall methylation state of the DNA molecules in the sample can be judged based on the amount of the uncut DNA molecules that can be separated relative to the amount of the separable DNA molecules in the sample not treated with the restriction endonuclease. For example, when treated with a methylation-sensitive restriction endonuclease, the amount of cut DNA molecules is relatively high (the amount of uncut DNA molecules is relatively low), indicating that the DNA molecules in the sample have a lower methylation level at the restriction endonuclease recognition site. In a preferred embodiment, the methylation capture probe is a μCaler probe (the design of the μCaler probe can be found in Chinese Patent Publication CN116083423A, which is incorporated herein by reference in its entirety). This probe includes a target-specific sequence, a first probe binding sequence at the 5' end of the target-specific sequence, and a second probe binding sequence at the 3' end of the target-specific sequence. The first probe binding sequence is at least partially complementary to the second probe binding sequence, so that when two capture probes or more capture probes bind to the target sequence in an adjacent manner, adjacent capture probes can form complementary binding through the first probe binding sequence and the second probe sequence. Relative to ordinary capture probes, the benefit of using μCaler probes is at least that the probe can significantly improve the ability of the probe to bind to the target, improve the hybridization capture efficiency of the target area, and improve the overall coverage uniformity and stability. The capture probe can usually be provided with a detachable label, such as biotin, so as to separate the target DNA molecule bound to the probe. The sequence information of the different target DNA molecules separated can be obtained by sequencing, and the methylation status at the restriction endonuclease recognition site can be obtained at the same time. The mutation capture probe is a capture probe that includes a mutation site of interest in the targeted DNA molecule. Sequencing the DNA molecule captured by the mutation capture probe can obtain information about the mutation status of the specific mutation site. Preferably, the mutation capture probe is also a probe in the form of μCaler. The methylation capture probe and the mutation capture probe can be located in the same probe group to achieve simultaneous capture of their respective target sequences. In addition, in order to form a uniform detection result between different samples, the probe group used in this article can also include a normalizing probe.Preferably, the homogenized probe is also a μCaler format probe.

[0037] In some embodiments, the present invention provides a process for constructing a targeted methylation library based on methylation-sensitive restriction endonucleases, including Hpa I, Hpa II, HhaI, AciI, etc.

[0038] In some embodiments, the targeted capture system provided herein is targeted at capturing non-transformed libraries, capturing original DNA sequences, and all CpG sites in restriction endonuclease recognition sites in the target regions of the captured fragments are methylated, thereby detecting information on methylation modification in the target regions.

[0039] In some embodiments, the methods provided herein are used to detect mutations in DNA samples, and the mutation types include base substitutions, chromosome copy number variation analysis, insertion / deletion, microsatellite instability, or fusion genes.

[0040] In some embodiments, the capture probe used is designed for the original DNA chain, and for the detection of methylation-related sites, the targeted capture probe needs to cover the corresponding methylation-sensitive restriction endonuclease cleavage site.

[0041] In some embodiments, two different libraries are used for mutation and methylation co-detection, and the design of the mutation capture probe does not need to take into account the design of the methylation capture probe; in some embodiments, the same library is used for mutation and methylation co-detection, and the mutation capture probe cannot cover the methylation-sensitive restriction endonuclease recognition sequence related to methylation detection.

[0042] In some embodiments, this article provides a targeted methylation library construction process based on methylation-sensitive restriction endonucleases, through which the sequencing depth of CpG sites can be detected, and the methylation level of CgG sites in samples can be analyzed using controls.

[0043] In some embodiments, the methods provided herein use a molecular tag-containing adapter module, and the molecular tag filters background noise and is suitable for detecting low-frequency mutation signals.

[0044] The targeted capture library construction process described in this article is shown in Figure 1. This process is suitable for detecting methylation status and mutation signals in target regions of physically fragmented gDNA samples, plasma free DNA, or circulating tumor ctDNA samples. Fragmented samples are used for library construction using the Nadprep Universal DNA Library Construction Kit. The library construction process is divided into two protocols. Workflow A involves end-repair plus A and adapter ligation. The adapter-ligated products are digested with methylation-sensitive restriction endonucleases such as Hpa I, Hpa II, Hha I, and Aci I. Another group, which is not digested, serves as a control group. PCR amplification is performed on both sets of products, and index sequences are added. The amplified products are hybrid captured using the μCaler hybrid capture system. All probes are designed using the μCaler probe design protocol. Probes are designed for the original DNA sequence, covering methylation-sensitive restriction endonuclease cleavage sites for methylation status detection and mutation detection sites for mutation signal detection. Workflow B involves digestion with methylation-sensitive restriction endonucleases such as Hpa I, Hpa II, Hha I, and Aci I. The digestion products are purified and recovered, and then library construction is performed. The library products are then hybridized and captured using the μCaler hybrid capture system. All probes are designed using the μCaler probe design, targeting the original DNA sequence. The probes cover methylation-sensitive restriction endonuclease cleavage sites for methylation status detection and mutation detection sites for mutation signal detection. The captured library is sequenced on an Illumina or MGI platform sequencer.

[0045] For the capture and mutation co-detection experimental process and the corresponding experimental design scheme, please refer to Figure 2. A. Start the experiment according to the experimental process described in Figure 1; after the adapter product is connected, it is digested with a methylation-sensitive restriction endonuclease. The library constructed from the digested products is used for methylation status detection, and the non-digested library is used for mutation detection; B. Start the experiment according to the experimental process described in Figure 1; after the adapter product is connected, it is digested with a methylation-sensitive restriction endonuclease. The library constructed from the digested products is used for methylation status and mutation detection status analysis. C. The probe design idea of ​​this system is to perform methylation detection. The probe needs to cover the methylation-sensitive restriction endonuclease cleavage site. For mutation site detection, the probe covers the gene site to be detected. If the experimental process B is adopted, the design of the mutation detection probe must take into account methylation detection. The designed probe cannot cover the methylation-sensitive restriction endonuclease cleavage site.

[0046] The use of this system for the co-detection process of mutations and methylation has obvious advantages over traditional schemes. See Figure 3 for details, which compares the experimental process of mutation and methylation detection using traditional detection schemes and the scheme adopted by this system; the process of mutation and methylation detection using the traditional detection scheme (Figure 3A) requires the construction of two sets of libraries and the conduct of two sets of hybridization capture experiments. The methylation library uses methylated-modified adapters, which are relatively expensive. The adapter ligation products are processed using the BS (experimental time, 2 hours) or EM (experimental time, 8 hours) conversion modules. The BS conversion process is relatively cumbersome and the conversion damage is relatively severe. Using this solution will lose a lot of original sample information. The EM conversion module has lower conversion damage. It is recommended to use NEB's enzymatic conversion module (NEBNext Enzymatic Conversion module) to convert unmethylated C bases into U bases. PCR amplification is performed using an amplification enzyme that can recognize U bases (KAPA HiFi HotStart Uracil Mix). The mutation detection library uses a conventional adapter module. Given that the DNA sequence of the converted library has changed, the probe used in hybridization capture is designed for the converted DNA sequence. The methylation library and DNA library must use independent hybridization capture systems for experiments. This system's mutation and methylation co-detection protocol (Figure 3B) uses conventional DNA adapters and MSRE for enzyme digestion (experimental time: 1 hour) to distinguish methylated and unmethylated C bases. The system constructs a DNA library, or the adapter-ligated product is divided into two aliquots, one of which is digested and amplified, while the other is directly amplified. Both amplified products can be hybridized on the same hybridization capture system. Traditional protocols for mutation and methylation detection can take 2-3 days, but this system can shorten the experimental time to 1 day. This system significantly reduces wet lab time, simplifies experimental procedures, and saves reagent costs, offering significant advantages.

[0047] Methylation level analysis protocol: After digestion, use non-digested samples with varying methylation levels as controls to calculate methylation levels. Methylation level calculation: Each site is normalized using an internal reference gene, with the normalized depth per CpG site for the digested samples divided by the normalized depth per CpG site for the control samples.

[0048] Mutation Detection Analysis Plan: Use Vardict or GATK software for call analysis. When using Vardict, use hg19 as the bed file and display the hg19 coordinates. When using GATK, use the control sample call points.

[0049] This article aims to develop a technical solution for co-detecting mutations and methylation in the same hybridization capture system. Compared with traditional detection technology solutions, it shortens detection time, simplifies experimental procedures, improves sample utilization, reduces reagent costs, and has broad market application prospects.

[0050] General experimental steps:

[0051] Step 1: Sample fragmentation

[0052] DNA sample fragmentation can be performed according to laboratory conditions. Covaris is recommended. TM Use a DNA ultrasonic disruptor to fragment the sample into products with an average fragment length of 200-250 bp. gDNA or FFPE DNA fragments proceed to step 2 after fragmentation. cfDNA samples proceed directly to step 2.

[0053] Step 2: End Repair & A Addition

[0054] 1. Take out End Repair & A-Tailing Buffer and dissolve it at room temperature, mix well, and place on ice until ready to use.

[0055] 2. Take out End Repair & A-Tailing Enzyme and place it on ice to thaw naturally. Mix well and centrifuge briefly for later use.

[0056] 3. Prepare the reaction system in a 0.2 mL PCR tube on ice according to the table below:

[0057] Note: If the amount of DNA is less than 20 μL, add Nuclease Free Water to make up to 20 μL.

[0058] 4. Mix well and centrifuge briefly to allow all the reaction solution to settle at the bottom of the PCR tube.

[0059] 5. Start the following reaction program (Cycling Program I) on the PCR instrument. When the temperature stabilizes at 20°C, place the PCR tube into the PCR instrument:

[0060] Note: No heated cover is required when the 20°C program is running, and the heated cover is 70°C when the 65°C program is running.

[0061] Step 3: Connect the connector

[0062] 1. Take out the Ligation Buffer and dissolve it at room temperature, mix well, and place on ice for later use.

[0063] Note: Ligation Buffer is very viscous. Pipette aspiration and release should be slow and steady to ensure accurate volume.

[0064] 2. Take out DNA Ligase and place it on ice to thaw naturally, mix well, and centrifuge briefly for later use.

[0065] 3. Remove the PCR tube from step 2 from the PCR instrument, place it on ice, and prepare the reaction system according to the following table:

[0066] Step 4: Purification of ligation product

[0067] Use 0.5×Beads for purification and recovery. The purification process is as follows:

[0068] 1. Add 20 μL of the ligation reaction product from step 3. SP Beads, mix well, and incubate at 20-25°C for 10 min.

[0069] 2. Centrifuge the PCR tube briefly and place it on a magnetic rack for 5 minutes until the liquid is completely clear. Use a pipette to remove and discard the supernatant.

[0070] Note: It must be fully clarified that the placement time must be adjusted for different brands of magnetic racks.

[0071] 3. Slowly add 150 μL of 80% ethanol along the side of the PCR tube, being careful not to disturb the magnetic beads. Let it stand for 30 seconds and use a pipette to remove and discard the supernatant.

[0072] 4. Repeat step 3 once.

[0073] 5. Centrifuge the PCR tube briefly and place it on a magnetic rack. Use a 10 μL pipette tip to remove a small amount of residual ethanol, being careful not to absorb the magnetic beads.

[0074] 6. Open the PCR tube cap and let it stand at 20-25℃ for about 2-3 minutes until the ethanol evaporates completely.

[0075] 7. Remove the PCR tube and add 44 μL of Nuclease Free Water to the PCR tube. Use a pipette to evenly resuspend the magnetic beads and incubate at 25°C for 2 minutes.

[0076] 8. Centrifuge the PCR tube briefly and place it on a magnetic rack for 2 minutes until the liquid is completely clear. Use a pipette to carefully transfer the supernatant to a new 0.2 mL PCR tube.

[0077] Step 5: Digestion with methylation-sensitive restriction enzymes

[0078] 1. Take out MeEnzyme & MeBuffer and place them on ice to dissolve naturally (NEB restriction endonuclease), mix well, and centrifuge instantly for later use.

[0079] 2. Set up the reaction system according to the table below in a 0.2 mL PCR tube placed on ice, using a methylation-sensitive restriction endonuclease. The system is as follows:

[0080] 3. Start the following reaction program on the PCR instrument and place the PCR tube into the PCR when the temperature stabilizes at 37°C: 37°C for 1 hour; 80°C for 20 minutes.

[0081] Step 6: Purification of enzyme digestion products

[0082] Use 1×Beads for purification and recovery. The purification process is shown in step 4. Use 20μL Nuclease-Free water for elution.

[0083] Step 7: PCR amplification of enzyme digestion products

[0084] 1. Take out 2×HiFi PCR Master Mix and Thaw the Universal UDI-Index Primer Mix naturally on ice, mix well, and centrifuge briefly.

[0085] 2. Prepare PCR amplification mix in a 0.2 mL PCR tube placed on ice according to the following table:

[0086] 3. Place the PCR tube into the PCR instrument and start the following program:

[0087] Step 8: Purification of amplified products

[0088] Use 1×Beads for purification and recovery. The purification process is shown in step 4. Use 20μL Nuclease-Free water for elution.

[0089] Step 9: Library hybridization

[0090] 1. Prepare the hybridization reaction system according to the following table:

[0091] 2. Vortex the hybridization reaction mixture for more than 10 seconds, centrifuge it, and collect the reaction mixture at the bottom of the PCR tube (avoid generating bubbles).

[0092] 3. Place the PCR tube into the PCR instrument and start the following reaction program: 98℃ for 2 minutes; 60℃ for 1 hour.

[0093] Step 10: Library capture and elution

[0094] Magnetic bead washing

[0095] 1. Vortex the Streptavidin Beads for 15 seconds to ensure complete mixing.

[0096] 2. Take n × 25 μL Streptavidin Beads and mix and wash in a 0.2 mL centrifuge tube (n is the number of captured libraries, and n < 5)

[0097] Note: When n>5, it must be divided into multiple tubes for mixed cleaning.

[0098] 3. Place the Streptavidin Beads on a magnetic rack and let it stand for about 2 minutes. When the liquid is completely clear, discard the supernatant using a pipette.

[0099] 4. Remove the centrifuge tube from the magnetic stand, add 100 μL preheated Wash buffer A, and mix gently by pipetting for more than 10 times.

[0100] 5. Place the centrifuge tube on the magnetic stand and let it stand for about 2 minutes. When the liquid is completely clear, use a pipette to discard the supernatant.

[0101] 6. Repeat steps 4 and 5 once.

[0102] 7. Centrifuge the tube briefly and remove all Wash buffer A at the bottom of the tube with a 10 μL pipette tip. 8. Take n×8 μL uHyb#l to resuspend the Streptavidin Beads and gently pipette and mix for more than 10 times.

[0103] Magnetic bead capture

[0104] 1. After 1 hour of hybridization reaction, enter the capture phase and keep the PCR instrument running.

[0105] 2. While keeping the PCR tube in the PCR instrument, take 8 μL of resuspended Streptavidin Beads and immediately add it to each hybridization reaction solution. Gently pipette and mix for more than 10 times.

[0106] 3. Incubate at 60°C for 10 minutes.

[0107] 4. After the incubation is completed, remove the PCR tube from the PCR instrument and place it on a magnetic stand for 2 minutes. When the liquid is completely clear, use a pipette to discard the supernatant as much as possible.

[0108] Elution

[0109] 1. Remove the PCR tube from the magnetic stand, add 150 μL preheated Wash Buffer A, and mix gently by pipetting for more than 10 times (avoid bubbles).

[0110] 2. Place the PCR tube on a magnetic rack and let it stand for 2 minutes. Once the liquid is completely clear, discard the supernatant using a pipette. 3. Remove the PCR tube from the magnetic rack and add 100 μL of preheated Wash Buffer A. Gently pipette and mix at least 10 times. Transfer the reaction solution to a new PCR tube.

[0111] Note: Try to avoid generating bubbles in this step. Bubbles contacting the tube cap may reduce the target hit rate.

[0112] 3. Place the PCR tube into the PCR instrument and incubate at 60°C for 3 minutes.

[0113] 4. Place the PCR tube into the PCR instrument and incubate at 60°C for 3 minutes.

[0114] 5. After the incubation is completed, remove the PCR tube from the PCR instrument and place it on a magnetic rack for 2 minutes. Wait until the liquid is completely clear and discard the supernatant using a pipette.

[0115] 6. Add 150 μL of room temperature Wash Buffer B to the PCR tube and mix gently by pipetting up and down 10 times.

[0116] 7. Place the PCR tube on a magnetic stand and let it stand for 2 minutes. When the liquid is completely clear, discard the supernatant using a pipette.

[0117] 8. Centrifuge the PCR tube briefly and place it on a magnetic rack. Use a 10 μL pipette tip to remove a small amount of residual liquid, being careful not to absorb the magnetic beads.

[0118] 9. Add 22.5 μL Nuclease Free Water and gently blow for more than 10 times to resuspend the magnetic beads.

[0119] Step 11: PCR amplification of hybrid capture library

[0120] 1. Take out 2×HiFi PCR Master Mix and Thaw the Universal UDI-Index Primer Mix naturally on ice, mix well, and centrifuge briefly.

[0121] 2. Prepare PCR amplification mix in a 0.2 mL PCR tube placed on ice according to the following table:

[0122] 3. Place the PCR tube into the PCR instrument and start the following program:

[0123] Step 12: Purification of amplified products

[0124] Use 1×Beads for purification and recovery. The purification process is shown in step 4. Use 20μL Nuclease-Free water for elution.

[0125] Example: Mutation and methylation co-detection using standards

[0126] Two libraries were constructed using the OGTM800 standard. The library construction process is briefly described as follows: 40 ng of the standard after ultrasonic shearing was taken for end repair and A addition, and adapter ligation; the adapter ligation product was divided into two, one group was digested with the methylation-sensitive restriction endonuclease Hha I, and the other group was not digested as a control group. PCR amplification was performed on the two groups of products, and the Index sequence was added, Figure 4A. The amplified products were hybridized and captured using the μCaler hybrid Capture system, and three panels, 10K MePanel, Normalized Panel, and OGTM800Panel, were used to capture them simultaneously. Among them, the 10KB probe covers the methylation-sensitive restriction endonuclease cleavage site, the Normalized Panel is used for normalization, and the OGTM800 Panel is used for mutation detection analysis. For specific experimental steps, please refer to the experimental process. The probe design scheme refers to the Chinese patent disclosure "CN116083423A A probe for targeted enrichment of nucleic acids".

[0127] The MePanel probe sequences are as follows.

[0128] The Normalized Panel probe sequences are as follows.

[0129] Results Analysis: The OGTM-CK control group was not digested with a methylation-sensitive restriction enzyme. Samples from this group can be used for mutation detection analysis. The OGTM-MSRE digestion group was digested with a methylation-sensitive restriction enzyme. The OGTM800 Panel designed for this workflow does not include methylation-sensitive restriction enzyme sites. Samples from this group can be used for both methylation and mutation detection analysis. Figure 4B shows the on-target rate and Mappability, both of which were greater than 99%. Figure 4C shows the coverage depth for different experimental groups, with 0.2× Mean Covariance > 95% and 0.5× Mean Covariance > 70%. Figure 5 shows the sequencing depth and corresponding methylation levels for methylation-sensitive CpG sites within the target region of different libraries. Methylation levels were calculated as: digestion depth / control depth. (A) Average CpG methylation levels for the two digestion experimental groups; (B) Corresponding methylation levels for each CpG site. Figure 6 shows the consistency analysis of the mutation frequency detected and the theoretical mutation frequency. The designed probes cover 15 mutation sites, including 11 mutation sites, 2 fusion sites, and 2 copy number variations (base insertions and deletions), involving common mutation detection mutation sites in cancer. The corresponding mutation frequencies range from 1% to 7%. The OGTM-CK experimental group did not perform enzyme digestion, and the OGTM-MSRE experimental group used a methylation-sensitive restriction endonuclease for enzyme digestion. The mutation panel coverage sites selected in this example do not contain endonuclease recognition sites, so the detection results of both OGTM-CK and OGTM-MSRE groups can reflect the true mutation level of the sample. The consistency analysis results of the detected mutation frequency and the theoretical mutation frequency show that the results detected by different experimental groups are in line with theoretical expectations. OGTM-CK represents the mutation detection situation of the control group in Figure 2A. If the mutation detection site contains a methylation-sensitive restriction endonuclease digestion site, this experimental design is recommended. OGTM-MSRE represents the mutation detection results in Figure 2B. If the mutation detection site does not involve a methylation-sensitive restriction endonuclease cleavage site, this experimental design is recommended.

Claims

1. A method for simultaneously detecting the methylation state and mutation state of a DNA molecule in a sample, comprising: 1) adding adapter molecules to both ends of the DNA molecules in the sample to obtain an adapter ligation product sample; dividing the adapter ligation product sample into two parts: a first adapter ligation product sample and a second adapter ligation product sample; 2) treating the first adapter ligation product sample with one or more methylation-sensitive restriction endonucleases, so that when the DNA molecule is not methylated at the recognition site of the methylation-sensitive restriction endonuclease, an enzyme digestion reaction can be performed to obtain an enzyme digestion sample; the second adapter ligation product sample is not treated with the restriction endonuclease; 3) using primers specific to the adapter molecule and having an Index sequence to respectively amplify the enzyme digestion sample and the second adapter ligation product sample to obtain enzyme digestion sample amplification products and second adapter ligation product sample amplification products, respectively; mixing the enzyme digestion sample amplification products and the second adapter ligation product sample amplification products to obtain an amplification product mixture; 4) contacting the amplicon mixture with a probe set comprising one or more mutation capture probes and one or more methylation capture probes to obtain a capture, wherein the methylation capture probe targets a target sequence in the DNA molecule including the recognition site, and the mutation capture probe targets a target sequence in the DNA molecule including the mutation site; and 5) sequencing the captured object, determining the methylation state of the DNA molecule including the recognition site by the sequencing depth ratio of the recognition sites from the enzyme-cut sample amplicon and the second connector-ligated product sample amplicon, and determining the mutation state by the sequencing result of the mutation site.

2. The method of claim 1, wherein the mutation capture probe and / or the methylation capture probe comprises a target-specific sequence, a first probe binding sequence located at the 5' end of the target-specific sequence, and a second probe binding sequence located at the 3' end of the target-specific sequence, and the first probe binding sequence is at least partially complementary to the second probe binding sequence, so that when two or more of the mutation capture probes and / or the methylation capture probes bind to their target sequences in an adjacent manner, the adjacent mutation capture probes and / or the methylation capture probes can form complementary binding through the first probe binding sequence and the second probe sequence.

3. The method of claim 1 or 2, wherein the probe set further comprises one or more normalization probes.

4. The method according to any one of claims 1 to 3, wherein the length of the first probe binding sequence and the second probe binding sequence is 8-30 nt.

5. The method according to any one of claims 1 to 4, wherein the target-specific sequence has a length of 20-80 nt.

6. The method according to any one of claims 1 to 5, further comprising fragmenting the DNA molecule before step 1).

7. The method of any one of claims 1 to 6, wherein the methylation-sensitive restriction endonuclease is selected from the group consisting of Hpa I, Hpa II, Hha I, Aci I, and any combination thereof.

8. The method of any one of claims 1-7, wherein the sample comprises ctDNA.

9. The method according to any one of claims 1 to 8, wherein the methylation status comprises whether methylated and / or the methylation level.

10. The method according to any one of claims 1 to 9, wherein the mutation status comprises whether a mutation exists and / or the type of mutation.

11. The method according to any one of claims 1 to 10, wherein the mutation type is selected from the group consisting of insertion, deletion and substitution of bases, chromosome copy number variation, microsatellite instability and fusion gene.

Citation Information

Patent Citations

  • Probe for targeted enrichment of nucleic acid

    CN116083423A

  • Method, probe library and kit for detecting tumor ctDNA methylation with high throughput and high sensitivity

    CN114214408A

  • Method for detecting methylation and mutation states of DNA sample

    CN116751862A

  • Method for detecting mutation and methylation of tumor specific gene in ctdna

    WO2021073490A1

  • Encoded nucleic acid methylation assays

    WO2023096671A1

Cited By

  • Methylation and mutation common detection data analysis method, device, equipment and medium

    CN121662177A